Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.

MLA

Qiu, Miao-Zhen, et al. “Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.” JAMA Oncology, vol. 8, no. 7, July 2022, pp. 1042–46. EBSCOhost, https://doi.org/10.1001/jamaoncol.2022.0503.

APA

Qiu, M.-Z., Zhang, Y., Guo, Y., Guo, W., Nian, W., Liao, W., Xu, Z., Zhang, W., Zhao, H.-Y., Wei, X., Xue, L., Tang, W., Wu, Y., Ren, G., Wang, L., Xi, J., Jin, Y., Li, H., Hu, C., & Xu, R.-H. (2022). Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncology, 8(7), 1042–1046. https://doi.org/10.1001/jamaoncol.2022.0503

Chicago

Qiu, Miao-Zhen, Yang Zhang, Ye Guo, Wei Guo, Weiqi Nian, Wangjun Liao, Zhongyuan Xu, et al. 2022. “Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.” JAMA Oncology 8 (7): 1042–46. doi:10.1001/jamaoncol.2022.0503.